The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice

References

• Bazzi W, Sabra A, Zahreddine L, Khairallah MT, Baroud M, Hadi U, Matar GM. 2013. The inhibitory effect of micafungin on biofilm formation by Pseudomonas aeruginosa. Biofouling. 29:909–915. doi:10.1080/08927014.2013.816299
   PubMed Web of Science ®Google Scholar
• Beaudoin T, Zhang L, Hinz AJ, Parr CJ, Mah T. 2012. The biofilm-specific antibiotic resistance gene ndvB is important for expression of ethanol oxidation genes in pseudomonas aeruginosa biofilms. J. Bacteriol. 194:3128–3136. doi:10.1128/JB.06178-11
   PubMed Web of Science ®Google Scholar
• Bonfiglio G. 2001. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy. 47:239–242.10.1159/000048529
   PubMed Web of Science ®Google Scholar
• Chen TL, Fung CP, Lee SD. 2011. Spontaneous eradication of a NDM-1 positive Klebsiella pneumoniae that colonized the intestine of an asymptomatic carrier. J. Chin. Med. Assoc. 74:104. doi:10.1016/j.jcma.2011.01.022
   PubMed Web of Science ®Google Scholar
• Cockerill FA, Wikler MA, Bush K, Dudley MN, Eliopoulos GM, Hardy DJ, Hecht DW, Hindler JA, Patel JB, Powell M, et al. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Clin. Lab. Stand. Inst. 31:1–165.
   Google Scholar
• Coulon C, Vinogradov E, Filloux A, Sadovskaya I. 2010. Chemical analysis of cellular and extracellular carbohydrates of a biofilm-forming strain Pseudomonas aeruginosa PA14. PLoS ONE. 5:1–10. doi:10.1371/journal.pone.0014220
   Web of Science ®Google Scholar
• Daas H, Abuhmaid F, Zervos M. 2009. Successful treatment of Candida parapsilosis and Pseudomonas aeruginosa infection using medical and surgical management in an injecting drug user with mitral and aortic valve endocarditis: a case report. J. Med. Case Rep. 3:6598. doi:10.1186/1752-1947-3-6598
   PubMedGoogle Scholar
• Davies SN, Martin D, Millar JD, Aram JA, Church J, Lodge D. 1988. Differences in results from in vivo and in vitro studies on the use-dependency of N-methyl aspartate antagonism byMK-801and other phencyclidine receptor ligands. Eur. J. Pharmacol. 145:141–151. doi:10.1016/0014-2999(88)90225-7
   PubMed Web of Science ®Google Scholar
• El Solh AA, Alhajhusain A. 2009. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother. 64:229–238. doi:10.1093/jac/dkp201
   PubMed Web of Science ®Google Scholar
• Griffith DC, Corcoran E, Lofland D, Lee A, Cho D, Lomovskaya O, Dudley MN. 2006. Pharmacodynamics of levofloxacin against pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated mics always predict reduced in vivo efficacy? Antimicrob. Agents. Chemother. 50:1628–1632. doi:10.1128/AAC.50.5.1628-1632.2006
   PubMed Web of Science ®Google Scholar
• Høiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. 2001. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3:23–35.10.1016/S1286-4579(00)01349-6
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Takata T, Tomoyose T, Masuda M, Nakachi S, Koga S, Tsukada J, Matsuura A, Utsunomiya A, Saburi Y, Tamura K. 2006. The efficacy of micafungin as an empiric therapy for febrile neutropenic patient’s refractory to antibacterial agents. Jpn. J. Chemother. 54:125–128. doi:10.11250/chemotherapy1995.54.125
   Google Scholar
• Lister PD, Wolter DJ. 2008. Resistance challenges threatening the treatment of Pseudomonas aeruginosa infections with levofloxacin: the role of a levofloxacin-imipenem combination for prevention of resistance. [cited 2015 Oct]. Available from: http://www.infectweb.com/only/artsrv2008_3.pdf
   Google Scholar
• Mennink-Kersten MASH, Ruegebrink D, Verweij PE. 2008. Pseudomonas aeruginosa as a cause of 1,3-ß-D-glucan assay reactivity. Clin. Infect. Dis. 46:1930–1931. doi:10.1086/588563
   PubMed Web of Science ®Google Scholar
• Mikkelsen H, Sivaneson M, Filloux A. 2011. Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ. Microbiol. 13:1666–1681. doi:10.1111/j.1462-2920.2011.02495.x
   PubMed Web of Science ®Google Scholar
• Nowotny A. 1979. Determination of toxicity. In: Basic exercises in immunochemistry. New York: Springer; p. 303–305.
   Google Scholar
• Polak S. 2013. In vitro to human in vivo translation – pharmacokinetics and pharmacodynamics of quinidine. ALTEX. 30:309–318. 10.14573/altex.2013.3.309
   PubMedGoogle Scholar
• Pomahac B, Pribaz J, Eriksson E, Bueno EM, Diaz-Siso J, Rybicki FJ, Annino DJ, Orgill D, Caterson EJ, Caterson SA, et al. 2012. Three patients with full facial transplantation. New England J. Med. 366:715–722. doi:10.1056/NEJMoa1111432
   PubMed Web of Science ®Google Scholar
• Rasamiravaka T, Labtani Q, Duez P, El Jaziri M 2015. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. BioMed Res. Int. 2015:1–17. doi:10.1155/2015/759348
   Web of Science ®Google Scholar
• Tennenberg AM, Davis NB, Wu S-, Kahn J. 2006. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr. Med. Res. Opin. 22:843–850. doi:10.1185/030079906X100195
   PubMed Web of Science ®Google Scholar
• Vasseur P, Soscia C, Voulhoux R, Filloux A. 2007. PelC is a Pseudomonas aeruginosa outer membrane lipoprotein of the OMA family of proteins involved in exopolysaccharide transport. Biochimie. 89:903–915. doi:10.1016/j.biochi.2007.04.002
   PubMed Web of Science ®Google Scholar
• Walton MA, Villarreal C, Herndon DN, Heggers JP. 1997. The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa. Burns. 23:225–227.10.1016/S0305-4179(96)00126-X
   PubMed Web of Science ®Google Scholar
• Wei Q, Ma LZ. 2013. Biofilm matrix and its regulation in Pseudomonas aeruginosa. Int. J. Mol. Sci. 14:20983–21005. doi:10.3390/ijms141020983
   PubMed Web of Science ®Google Scholar
• Zahreddine LT, Khairallah MT, Sabra AH, Baroud M, Hadi U, Matar GM. 2012. Expression levels of virulence factors with up-regulation of hemolytic phospholipase C in biofilm-forming Pseudomonas aeruginosa at a tertiary care center. J. Appl. Res. 12:87–97.
   Google Scholar
• Zhao T, Liu Y. 2010. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 10:140. doi:10.1186/1471-2180-10-140
   Web of Science ®Google Scholar